Despite the successful advancement to the clinical trial phase, the development of resistance to MDM2 inhibitors, which induces mutations in TP5314 and triggers an urgent need for the establishment of more effective drug combinations for wt-TP53 cancers. This evidence concerns the gene MDM2 and cancer.